Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm, Residual 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 73 Rituximab 59 Specimen Handling 49 Biopsy 42 Doxorubicin 41 Vincristine 40 Magnetic Resonance Spectroscopy 39 Prednisone 36 venetoclax 28 obinutuzumab 27 fludarabine 26 ibrutinib 22 Methotrexate 22 Dexamethasone 21 Cytarabine 21 Lenalidomide 20 blinatumomab 19 Etoposide 19 merphos 17 zanubrutinib 16 acalabrutinib 16 prednylidene 15 fludarabine phosphate 15 deltacortene 15 X-Rays 14 Mercaptopurine 14 Bendamustine Hydrochloride 14 pegaspargase 13 Calcium Dobesilate 13 CT-P10 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

tisagenlecleucel × Lymphoid × 30 days × Clear all

NCT03876769 2026-06-02

CASSIOPEIA

Novartis

Phase 2 Active not recruiting

Burkitt Lymphoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡